Skip to main content
. Author manuscript; available in PMC: 2016 Sep 13.
Published in final edited form as: J Neurooncol. 2016 Jul 12;129(3):487–494. doi: 10.1007/s11060-016-2195-9

Table 1.

Baseline characteristics of patients with recurrent glioblastoma enrolled in study

Category Bevacizumab + CCNU Bevacizumab alone
# Previous recurrence
    1st 25 (71.4%) 24 (66.7%)
    2nd 10 (28.7%) 12 (33.3%)
Age
    ≤ 50 13 (37.1%) 13 (36.1%)
    > 50 22 (62.9%) 23 (63.9%)
KPS
    60-80 11 (31.4%) 13 (36.1%)
    90-100 24 (68.6%) 23 (63.9%)
Gender
    Male 11 (31.4%) 12 (33.3%)
    Female 24 (68.6%) 24 (66.7%)